-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 13th, Yahong Medicine announced that its oral drug APL-1202 and BeiGene Baizean® (tislelizumab) combined with neoadjuvant treatment of myometrial invasive bladder cancer (MIBC) clinical research application (IND) was approved by the Center for Drug Evaluation (CDE) of the State Drug Administration of China
.
The clinical trial application was approved by the U.
The study is an open-ended, multi-center international phase I/II clinical study.
The main research objectives include: assessing the safety of combination therapy for MIBC patients, the recommended dose and efficacy of phase II clinical research as a neoadjuvant treatment for MIBC
.
APL-1202 is an oral reversible MetAP2 inhibitor with anti-angiogenesis, anti-tumor activity and regulation of tumor immune microenvironment
.
Phase III clinical trials of first-line single-agent and second-line combined chemotherapy infusion for the treatment of non-muscular invasive bladder cancer (NMIBC) are currently being carried out in China
According to the 2020 Chinese Society of Clinical Oncology (CSCO) Urothelial Carcinoma Diagnosis and Treatment Guidelines, for patients who can tolerate radical bladder cancer surgery, radical cystectomy (Radical Cystectomy) is performed after neoadjuvant chemotherapy if they are tolerant of cisplatin.
, RC) is a Class I recommended treatment plan for MIBC treatment.
The commonly used chemotherapy regimen is the GC regimen (gemcitabine + cisplatin)
.
However, cisplatin drugs can easily cause serious side effects such as renal dysfunction, peripheral neuropathy, bone marrow suppression, and some patients are intolerant to it